Phase I Trial of PCLX-001 in B-cell Non-Hodgkin Lymphoma and Advanced Solid Malignancies
Status:
Recruiting
Trial end date:
2023-03-31
Target enrollment:
Participant gender:
Summary
This is a phase I dose-escalation study of oral PCLX-001, conducted in a multicenter,
non-randomized, open-label, non-controlled design. The study is comprised of two parts: Part
A (single-agent dose escalation) and Part B (single-agent expansion cohorts).